Literature DB >> 19728180

Cumulative morbidity and late mortality in long-term survivors of exocrine pancreas cancer.

Nisha L Jacobs1, Florencia G Que, Robert C Miller, Santhi Swaroop Vege, Michael B Farnell, Aminah Jatoi.   

Abstract

BACKGROUND: Less than 5% of patients diagnosed with exocrine pancreas cancer live to be long-term survivors (5+ years after diagnosis). As a result, few studies have focused on these patients' cumulative, cancer-related morbidity and late mortality. This descriptive study was undertaken to explore such issues.
METHODS: One thousand eight hundred thirty consecutive patients who had exocrine pancreas cancer had been seen at the Mayo Clinic between 1995 and 2001 and who had well-documented evidence of having lived for 5+ years were the focus of this study.
RESULTS: Only 85 patients (4.6%) met all the above criteria. These patients had a median age of 65 years with a slight female predominance (53%). Eighty-one (95%) were treated with surgery, 42 (49%) with chemotherapy, and 41 (48%) with radiation. Cumulative morbidity included one or more subsequent surgeries in 17 patients (20%), one or more major infections in 14 (16%), diabetes in 39 (45%), depression in 16 (19%), and a second malignancy in 17 (20%). Twenty-nine patients were deceased at the time of this report; 15 (18%) died from recurrent pancreas cancer more than 5 years after their original diagnosis.
CONCLUSION: Long-term survivors of exocrine pancreas cancer confront notable rates of cumulative morbidity, which include subsequent major surgeries, major infections, diabetes, depression, and second malignancies, as well as late deaths from pancreas cancer itself.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19728180     DOI: 10.1007/s12029-009-9082-y

Source DB:  PubMed          Journal:  J Gastrointest Cancer


  9 in total

Review 1.  Are we improving the long-term burden of Hodgkin's lymphoma patients with modern treatment?

Authors:  Berthe M P Aleman; Flora E van Leeuwen
Journal:  Hematol Oncol Clin North Am       Date:  2007-10       Impact factor: 3.722

2.  Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.

Authors:  H A Burris; M J Moore; J Andersen; M R Green; M L Rothenberg; M R Modiano; M C Cripps; R K Portenoy; A M Storniolo; P Tarassoff; R Nelson; F A Dorr; C D Stephens; D D Von Hoff
Journal:  J Clin Oncol       Date:  1997-06       Impact factor: 44.544

Review 3.  Evolution and current status of the Whipple procedure: an update for gastroenterologists.

Authors:  S M Strasberg; J A Drebin; N J Soper
Journal:  Gastroenterology       Date:  1997-09       Impact factor: 22.682

4.  Combined-modality therapy versus radiotherapy alone for treatment of early-stage Hodgkin's disease: cure balanced against complications.

Authors:  Bridget F Koontz; John P Kirkpatrick; Robert W Clough; Robert G Prosnitz; Jon P Gockerman; Joseph O Moore; Leonard R Prosnitz
Journal:  J Clin Oncol       Date:  2006-02-01       Impact factor: 44.544

5.  Avoidance of premature death: a new definition for the proportion cured.

Authors:  P D Sasieni; J Adams; J Cuzick
Journal:  J Cancer Epidemiol Prev       Date:  2002

6.  Long-term survival after pancreatoduodenectomy for pancreatic adenocarcinoma: is cure possible?

Authors:  Thomas Schnelldorfer; Adam L Ware; Michael G Sarr; Thomas C Smyrk; Lizhi Zhang; Rui Qin; Rachel E Gullerud; John H Donohue; David M Nagorney; Michael B Farnell
Journal:  Ann Surg       Date:  2008-03       Impact factor: 12.969

7.  A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer.

Authors:  John P Neoptolemos; Deborah D Stocken; Helmut Friess; Claudio Bassi; Janet A Dunn; Helen Hickey; Hans Beger; Laureano Fernandez-Cruz; Christos Dervenis; François Lacaine; Massimo Falconi; Paolo Pederzoli; Akos Pap; David Spooner; David J Kerr; Markus W Büchler
Journal:  N Engl J Med       Date:  2004-03-18       Impact factor: 91.245

8.  Mortality associated with depression: a forty-year perspective from the Stirling County Study.

Authors:  Jane M Murphy; Jack D Burke; Richard R Monson; Nicholas J Horton; Nan M Laird; Alain Lesage; Arthur M Sobol; Alexander H Leighton
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2008-03-07       Impact factor: 4.328

9.  Obesity and undiagnosed diabetes in the U.S.

Authors:  Christina C Wee; Mary Beth Hamel; Annong Huang; Roger B Davis; Murray A Mittleman; Ellen P McCarthy
Journal:  Diabetes Care       Date:  2008-05-28       Impact factor: 19.112

  9 in total
  5 in total

1.  Management of afferent loop obstruction from recurrent metastatic pancreatic cancer using a venting gastrojejunostomy.

Authors:  Debbie Bakes; Christian Cain; Michael King; Xiang Da Eric Dong
Journal:  World J Gastrointest Oncol       Date:  2013-12-15

2.  Docetaxel- and 5-FU-concurrent radiotherapy in patients presenting unresectable locally advanced pancreatic cancer: a FNCLCC-ACCORD/0201 randomized phase II trial's pre-planned analysis and case report of a 5.5-year disease-free survival.

Authors:  Lucie Oberic; Frédéric Viret; Charlotte Baey; Marc Ychou; Jaafar Bennouna; Antoine Adenis; Didier Peiffert; Françoise Mornex; Jean-Pierre Pignon; Patrice Celier; Jocelyne Berille; Michel Ducreux
Journal:  Radiat Oncol       Date:  2011-09-26       Impact factor: 3.481

3.  Survival of patients with advanced pancreatic cancer after iodine125 seeds implantation brachytherapy: A meta-analysis.

Authors:  Quanli Han; Muhong Deng; Yao Lv; Guanghai Dai
Journal:  Medicine (Baltimore)       Date:  2017-02       Impact factor: 1.889

4.  Rare, long-term complication after pancreatoduodenectomy-a case report of cecal volvulus.

Authors:  Colleen P Nofi; Caroline Maloney; Michelle P Kallis; Anna T Levy; William H Nealon; Matthew J Weiss; Danielle K DePeralta
Journal:  J Surg Case Rep       Date:  2021-05-28

5.  Genetic analysis of subsequent second primary malignant neoplasms in long-term pancreatic cancer survivors suggests new potential hereditary genetic alterations.

Authors:  Martin Lovecek; Marketa Janatova; Pavel Skalicky; Tomas Zemanek; Roman Havlik; Jiri Ehrmann; Ondrej Strouhal; Petra Zemankova; Klara Lhotova; Marianna Borecka; Jana Soukupova; Hana Svebisova; Pavel Soucek; Viktor Hlavac; Zdenek Kleibl; Cestmir Neoral; Bohuslav Melichar; Beatrice Mohelnikova-Duchonova
Journal:  Cancer Manag Res       Date:  2019-01-10       Impact factor: 3.989

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.